ストックスクリーナーアプリを入手
54.04
0.24%
0.13
アフターアワーズ：
53.90
-0.14
-0.26%
前日終値:
$53.91
開ける：
$53.95
24時間の取引高:
1.12M
Relative Volume:
0.54
時価総額：
$4.32B
収益：
-
当期純損益:
$-269.44M
株価収益率:
-14.41
EPS:
-3.75
ネットキャッシュフロー:
$-262.63M
1週間 パフォーマンス:
-0.30%
1か月 パフォーマンス:
+17.48%
6か月 パフォーマンス:
+26.29%
1年 パフォーマンス:
+54.98%
1日の値動き範囲:
$53.93
$54.10
1週間の範囲:
$53.90
$54.20
52週間の値動き範囲:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
名前
Akero Therapeutics Inc
セクター
電話
650-487-6488
住所
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
AKRO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
54.04 | 4.32B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-04 | 再開されました | H.C. Wainwright | Buy |
| 2025-08-04 | 開始されました | TD Cowen | Buy |
| 2025-01-30 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-01-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-11-18 | 開始されました | Citigroup | Buy |
| 2024-04-22 | 再開されました | BofA Securities | Neutral |
| 2023-09-19 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-08-28 | 開始されました | UBS | Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-10-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-02-26 | 開始されました | Guggenheim | Buy |
| 2020-09-10 | 開始されました | Morgan Stanley | Overweight |
| 2020-07-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-07 | 開始されました | Chardan Capital Markets | Buy |
| 2020-07-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-02 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-10 | 開始されました | Canaccord Genuity | Buy |
| 2019-07-15 | 開始されました | Evercore ISI | Outperform |
| 2019-07-15 | 開始されました | JP Morgan | Overweight |
| 2019-07-15 | 開始されました | Jefferies | Buy |
| 2019-07-15 | 開始されました | ROTH Capital | Buy |
すべてを表示
Akero Therapeutics Inc (AKRO) 最新ニュース
Novo Nordisk, Akero Therapeutics filed HSR paperwork on Nov. 5 - MLex
Halper Sadeh LLC Encourages JAMF, CADE, AKRO, GES Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Is Akero Therapeutics Inc. stock attractive for growth ETFsTrade Ideas & Weekly High Momentum Picks - newser.com
Is Akero Therapeutics Inc. stock supported by innovation pipeline2025 Market Sentiment & AI Driven Stock Movement Reports - newser.com
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and Harmony Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting®? 2025 - MarketScreener
Akero Therapeutics presents new phase 2b trial data on efruxifermin at AASLD liver meeting 2025 - MarketScreener
Akero reports positive efruxifermin data for MASH at liver conference - Investing.com India
Akero (NASDAQ: AKRO) presents 96‑week data: CSPH risk improved, AI confirms fibrosis - Stock Titan
Heatmap analysis for Akero Therapeutics Inc. and competitors2025 Pullback Review & Verified Momentum Watchlists - newser.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qorvo, Inc. (Nasdaq – QRVO), First Foundation Inc. (NYSE – FFWM), Akero Therapeutics, Inc. (NasdaqAKRO), CoreCard Corporation (NYSE - GlobeNewswire Inc.
Can Akero Therapeutics Inc. (0K4) stock beat analyst consensusJuly 2025 Sector Moves & AI Driven Stock Movement Reports - newser.com
Can volume confirm reversal in Akero Therapeutics Inc.2025 Top Gainers & High Win Rate Trade Tips - newser.com
Is Akero Therapeutics Inc. (0K4) stock a contrarian opportunityJuly 2025 EndofMonth & Trade Opportunity Analysis Reports - newser.com
Will Akero Therapeutics Inc. (0K4) stock rise with strong economy2025 Pullback Review & Low Risk Growth Stock Ideas - newser.com
Can Akero Therapeutics Inc. stock hit record highs againQuarterly Trade Review & Low Risk Growth Stock Ideas - fcp.pa.gov.br
Can Akero Therapeutics Inc. (0K4) stock deliver strong annual returnsJuly 2025 Levels & Verified Chart Pattern Signals - newser.com
Will Akero Therapeutics Inc. stock gain from lower inflationMarket Sentiment Report & Reliable Price Action Trade Plans - newser.com
How rising interest rates impact Akero Therapeutics Inc. stock2025 Volatility Report & Free Technical Confirmation Trade Alerts - newser.com
Chart based analysis of Akero Therapeutics Inc. trendsJuly 2025 Drop Watch & Low Drawdown Trading Techniques - newser.com
How high can Akero Therapeutics Inc. stock goTrade Ideas & Weekly High Momentum Picks - newser.com
Will Akero Therapeutics Inc. stock sustain high P E ratios2025 Short Interest & Free Long-Term Investment Growth Plans - fcp.pa.gov.br
Will Akero Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Short Interest & Technical Entry and Exit Tips - newser.com
Using RSI to spot recovery in Akero Therapeutics Inc.July 2025 Short Interest & Low Risk High Reward Ideas - newser.com
Will Akero Therapeutics Inc. outperform the market2025 Technical Overview & Safe Capital Growth Stock Tips - newser.com
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) - Lelezard
Is Akero Therapeutics Inc. (0K4) stock included in top ETFs2025 Macro Impact & Low Drawdown Investment Strategies - newser.com
Why (AKRO) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Why Akero Therapeutics Inc. stock is recommended by analystsQuarterly Growth Report & Free Expert Verified Stock Movement Alerts - newser.com
Is Akero Therapeutics Inc. stock a buy before product launchesWeekly Trade Review & Weekly Watchlist for Hot Stocks - newser.com
Akero Therapeutics Inc (AKRO) 財務データ
収益
当期純利益
現金流量
EPS
Akero Therapeutics Inc (AKRO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Cheng Andrew | President and CEO |
Oct 10 '25 |
Option Exercise |
19.87 |
30,000 |
596,100 |
556,114 |
| Cheng Andrew | President and CEO |
Oct 10 '25 |
Sale |
53.98 |
30,000 |
1,619,340 |
526,114 |
| Graham G. Walmsley | Director |
Oct 08 '25 |
Option Exercise |
20.55 |
90,832 |
1,866,155 |
93,000 |
| Rolph Timothy | Chief Scientific Officer |
Oct 07 '25 |
Option Exercise |
28.35 |
12,500 |
354,375 |
179,071 |
| Rolph Timothy | Chief Scientific Officer |
Oct 07 '25 |
Sale |
46.08 |
12,500 |
576,001 |
166,571 |
| Cheng Andrew | President and CEO |
Oct 08 '25 |
Option Exercise |
0.61 |
52,212 |
32,110 |
526,114 |
5.44%
0.70%
大文字化:
|
ボリューム (24 時間):